The State of Pharma Content Operations 2026

Pharma teams keep producing more content, yet nearly 80% of approved assets are rarely or never used. Fragmented systems, long review cycles, and manual handovers keep the rest from reaching HCPs on time. The bottleneck now sits in how content moves through the organization, not in how much pharma content creation happens.

The State of Pharma Content Operations 2026 analyzes 6,856 anonymized workflow datapoints from more than 20 enterprise pharmaceutical and life sciences companies across a full 15-month planning cycle. It maps the six steps of the content supply chain and benchmarks three maturity stages against each one, giving leaders a practical framework for pharmaceutical content strategy from planning through activation. You will see what high-performing teams do differently at every step, including how they build a healthcare content repurposing strategy that converts approved assets into reusable modules, embed MLR upstream, and activate compliant content across Veeva Vault, SFMC, and CRM.

Whether you are refining a life sciences content marketing strategy or building content strategy for pharma from the ground up, the maturity model shows where your next investment returns the most. Score your operations against it and see where you stand.